Southern National Bancorp of Virginia Inc (SONA)

Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In MelanomaMay 5, 2026 7:17 AM
PR Newswire (Canada) /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/HALIFAX, NS, May 5, 2026 /CNW/ - Sona Nanotech Inc., (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), is pleased to announce its clinical strategy to further the development of its Targeted Hyperthermia Therapy ("THT") cancer treatment.  Based on both the success of Sona's first-in-human clinical study with THT, which demonstrated its ability to shrink and prime tumors immunogenically when used alone, and the published results from preclinical testing of Sona's THT showing the higher and more durable response rates that were observed when THT is combined with standard immunotherapies, the Company now intends to trial advanced applications of THT in two innovative clinical studies in melanoma patients combining THT with immunotherapy drugs.  With a view to assessing how THT's effectiveness and durability can be enhanced for late-stage melanoma sufferers, Sona will undertake its next clinical study of THT, (the "IGNITE-THT Study" - Immunotherapy + THT to Generate Novel Immune Tumor Eradication). In this study, Sona's THT would be administered in conjunction with a regimen of intratumoral and systemic dosing of the same immunotherapy drugs on which a cohort of patients had previously failed. The IGNITE-THT Study is expected to demonstrate the same safety and tolerability as experienced in the Company's previous clinical study, but with enhanced efficacy and long-term durability from the combination therapy anticipated after tumors are immunogenically activated by Sona's THT treatment (as experienced in the Company's recently published pre-clinical study). A second study, (the "PRIME-THT Study" - Precision Regional Immunotherapy for Melanoma Enhanced by THT) will assess the same concept but in newly diagnosed early-stage melanoma sufferers, which represents a much larger number of affected people worldwide (estimated by management to be up to 275,000 globally each year).  Patients in this study would be given THT in combination with intratumoral immunotherapy with a view to stopping tumors from spreading (metastasising) by THT activating strong immune responses prior to standard-of-care surgical tumor resection. In addition to evaluating the safety and tolerability of Sona's THT treatment in an 'up-front' (neo-adjuvant) setting, the PRIME-THT Study will also measure the immediate treatment effect and the long-term durability of responses related to this novel, early-stage, neo-adjuvant combination therapy. These new studies are designed to answer the same questions from different ends of the patient journey:  can THT convert immunogenically 'cold' tumors into tumors that respond to immunotherapies?  The IGNITE-THT Study will ask it for patients who have already failed on treatment and remain on immunotherapy's treatment plateau. The PRIME-THT Study asks it earlier, enabling and bringing the benefits of immunotherapy forward into the pre-resection window, where stopping metastases is still possible.Dr. Carman Giacomantonio, Sona's Chief Medical Officer, commented, "Having shown Sona's THT's ability to safely prime and shrink tumors in humans, we will now assess THT's ability to enable the efficacy of immunotherapy drugs, turning previously refractory tumors into responders. Our pre-clinical combination studies in multiple cancer model types have demonstrated success increasing immunotherapy response rates and response durability so we have good reason for optimism. Additionally, our intratumoral approach to administering the immunotherapy is expected to significantly reduce patient's typical immunotherapy-related side-effects."David Regan, Sona's CEO, commented, "These studies test the central question THT was built to answer: can we improve response rates to immunotherapy while lowering the well-recognized immunotherapy-related toxicities patients frequently experience? With stage IV melanoma patients having less than a 50% chance of surviving past five years due to low immunotherapy response rates, a plateau the field has not been able to break, and up to 20% of resected stage II melanoma patients developing metastases, we have an opportunity to improve the quality of life for hundreds of thousands of patients affected by this growing problem. Our goal with these studies is to demonstrate the potential for Sona's THT to improve on the current standards-of-care in multiple indications in our first solid cancer target." Early result read-outs from the IGNITE-THT and PRIME-THT studies are expected within six and eight months of their initiation, respectively.What This Means for Sona's Shareholders:An expansion to a second cancer indication. Demonstrating THT in both early and late-stage melanoma indications shows a greater breadth of potential treatment market size.Two near-term valuation catalysts. A clear strategy to demonstrate long-term potential to the investment community with relatively near-term deliverables.What This Means for Those Living With Melanoma:Potential for greater chances of cure. Priming tumors with THT to engage the immune system prior to the administration of today's best immunotherapy drugs could result in higher response rates to those drugs.Potential for reduced risk of metastases. Pre-treating early-stage melanoma tumors could reduce the chances that the cancer spreads to lymph nodes prior to standard-of-care resection.The Company also continues to lay the groundwork for a larger scale, clinical trial in Canada for late-stage melanoma patients, working with Health Canada to secure the required investigational testing authorization ("ITA").  Feedback received from Health Canada is guiding the Company's ITA application for a combination strategy clinical trial which it expects to begin early in 2027 and run for up to 18 months with multiple read-out milestones.The Company will hold an investor webinar on Thursday, May 7th, 2026, at 1pm ET.  Registration link: https://bit.ly/4mZSoN2.About Sona Nanotech Inc.
Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, that uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion, an approach aligned with the melanoma research community's active focus on converting immunogenically 'cold' tumors, which resist immunotherapy, into 'hot' tumors that the immune system can recognize and attack, thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy; impact and effectiveness of Sona's THT cancer treatment; the timing and receipt of expected positive histological results supporting first-in-man treatment results obtained to date, including the anticipated design, conduct, and outcomes of the IGNITE-THT and PRIME-THT clinical studies; potential future applications of Sona's THT cancer treatment, including the estimated addressable patient population for early-stage melanoma; the timing and completion of Sona's proposed Canadian pilot study and Sona's preclinical and clinical study plans and the potential market impacts of such studies. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to secure the remaining required regulatory approvals for its clinical trials, including the ITA; enroll study participants in a timely manner, successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, the risk that THT may not prove to have the benefits currently reported and anticipated, and general economic, market, competitive and business conditions . There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.SOURCE Sona Nanotech Inc. Original: Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In Melanoma

Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer ConferencesApril 27, 2026 7:00 AM
PR Newswire (Canada)

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/HALIFAX, NS, April 27, 2026 /CNW/ - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that its Chief Medical Officer, Dr. Carman Giacomantonio presented data from its first-in-human early feasibility study for its Targeted Hyperthermia Therapy cancer treatment at the American Association for Cancer Research ("AACR") last week in San Diego. Dr. Giacomantonio has also been accepted to present Sona's data at the American Society of Clinical Oncology ("ASCO") annual meeting May 29 – June 2, 2026, a conference centered on scientific innovation and its translation into practical patient-centered clinical application.







Dr. Giacomantonio commented, "AACR is the premier stage for sharing breakthrough science, and it was exciting to see our Targeted Hyperthermia Therapy align so well with the conference's focus on overcoming immunotherapy resistance. The feedback we received on our clinical study was incredibly encouraging and confirms for us that we're on the right path toward offering new hope to patients who have run out of options. Next, we are delighted to have been invited to share our compelling data to the more industry-focused ASCO conference."The presentation highlights the initial safety, tolerability and anti-tumor activity from this study which demonstrated a complete response in treated indicative tumors in six out of ten late-stage melanoma patients who had previously failed on standard of care immunotherapy. This study is a critical milestone in the Company's mission to treat immunotherapy-resistant solid tumors in humans. A manuscript detailing these results is currently being prepared for submission to a leading peer-reviewed scientific journal.Sona's first-in-human study results speak to a persistent unmet need that remains the dominant conversation in the melanoma community. The Melanoma Research Alliance noted in October 2025 that roughly half of advanced melanoma patients still do not respond to — or develop resistance to — currently approved immunotherapies. Sona's study was conducted in patients from precisely this refractory group.Next month's ASCO annual meeting is the world's most significant gathering of oncology professionals, serving as the premier global stage for the unveiling of practice-changing clinical research. Each year, more than 40,000 oncology experts, patient advocates, and industry leaders from over 150 countries convene to present and discuss the latest advances in clinical cancer care. Known for its focus on the "bench-to-bedside" transition, the meeting features groundbreaking abstracts and clinical trial results that directly influence the standard of care for patients worldwide.About Sona Nanotech Inc.
Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. Sona's Targeted Hyperthermia Therapy (THT) uses proprietary gold nanorods that absorb infrared light to deliver precise heat directly to a tumor. This therapeutic heating (42-48°C) is designed to stimulate the immune system, shrink tumors, inactivate cancer stem cells, and increase blood flow to the site. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy, and Sona's preclinical and clinical study plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to secure the remaining required regulatory approvals for the Pilot Study, enroll study participants in a timely manner, successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.SOURCE Sona Nanotech Inc.

Original: Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences

Sona Nanotech Announces Appointment of Two Leading Oncologists To Its Scientific Advisory BoardApril 16, 2026 6:30 AM
PR Newswire (Canada)

/Not for distribution to United States newswire services or for dissemination in the United States/HALIFAX, NS, April 16, 2026 /CNW/ - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is honoured to announce the appointment of two renowned oncologists to its scientific advisory board: Dr. Michael Smylie and Dr. Jonathan Trites.







Dr. Michael Smylie is a leading medical oncologist at the Cross Cancer Institute in Edmonton and a clinical professor at the University of Alberta, renowned for his transformative work in melanoma research. He played a key role as a contributing investigator and co-author in the landmark CheckMate clinical trials—specifically CheckMate 067. This study is hailed as a turning point in oncology, as it proved that combining immunotherapy drugs could lead to long-term survival for patients with advanced melanoma, a condition once considered a terminal diagnosis.His work on the long-term outcomes and quality-of-life data from these trials has helped establish the current international standard of care, moving the needle from short-term treatment to the possibility of decade-long remission for many.Dr. Jonathan Trites is a head and neck oncologic and reconstructive surgeon based at the Queen Elizabeth II Health Sciences Centre in Halifax. As an Associate Professor at Dalhousie University, he has been a key figure in research advancing surgical techniques and outcomes for complex head and neck cancers. Dr. Trites's work primarily focuses on improving the precision and functional outcomes of cancer surgeries. He is a leader in using minimally invasive techniques for tumors of the upper aerodigestive tract. His research has demonstrated that Transoral Laser Microsurgery (TLM) is a viable option for advanced-stage glottic cancer, achieving high rates of laryngeal preservation and excellent functional outcomes.  He has also published significant data on various squamous cell carcinomas, including early-stage laryngeal cancer and oropharyngeal cancer.Sona's Chief Medical Officer, Dr. Carman Giacomantonio, commented, "I am excited to have Dr. Smylie and Dr. Trites join our scientific advisory board.  I have had the privilege of working closely with both gentlemen over the past many years and have a tremendous amount of respect for the experience and wisdom they bring to our table.  The clinical course we are embarking upon is truly pioneering. Both Dr. Trites and Dr. Smylie have been pioneers throughout their careers in their respective fields, giving me and my team a tremendous amount confidence as we plan and begin to execute our clinical course going forward." About Sona Nanotech Inc.
Sona Nanotech, a nanotechnology life sciences company, is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion – thus enabling drugs to reach all tumor compartments more effectively. The size, shape, and surface chemistry of the nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy, Sona's preclinical and clinical study plans, future patent filings and its product development plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.SOURCE Sona Nanotech Inc.

Original: Sona Nanotech Announces Appointment of Two Leading Oncologists To Its Scientific Advisory Board

Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy SynergiesApril 13, 2026 7:29 AM
PR Newswire (Canada)

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/HALIFAX, NS, April 13, 2026 /CNW/ - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), is pleased to provide follow-up histology tissue analysis data from its first-in-human early feasibility study of its Targeted Hyperthermia Therapy ('THT') in late stage melanoma patients who had failed on standard immunotherapy protocols (the "Study").  An extensive multiplex histological tissue analysis conducted at Dalhousie University of representative tissues from Study patients showed extensive natural killer cell infiltration in tumor tissues biopsied after treatment with THT indicative of innate immune activation.  Also, analysis of samples from Study patients who only partially responded to the THT treatment showed a significant increase in T-regulatory cells and strong PD-L1 expression suggesting that these tumors may benefit from adding PD-1 immunotherapy in combination with Sona's THT treatment.







Dr. Carman Giacomantonio, Sona's CMO, commented, "We are very proud and excited to report that the detailed histological tissue analysis from representative patient samples validates our pre-clinical findings. Our analysis confirms that patients responding to Sona's THT treatment experienced a strong immunogenic response characterized by extensive innate immune activation with abundant macrophage infiltration and a robust natural killer cell infiltration. Notably, in partially responding patients, we observed a significant increase in T-regulatory cells and strong expression of PD-L1. The significance of this in response is these patients would be predicted to respond to PD-1 and CTLA-4 immunotherapy, particularly if administered in timely combination with our THT." These results, together with our pre-clinical modelling studies, give us great confidence that immunotherapy response rates, which are typically below 20% for colorectal cancer, can be increased by first priming tumors with Sona's THT therapy before administering immunotherapy, giving hope to the four out of five colorectal cancer sufferers for whom no treatment tends to work.".This histology tissue analysis, together with the Study's protocol and other findings are now being prepared for submission to a scientific journal for peer review and publication.In the Study, ten advanced-stage melanoma patients, all of whom were failing to respond to standard immunotherapy treatment, were recruited into this early feasibility study. Under the study protocol, patients had up to four tumors treated with Sona's THT on days one and eight of the Study. By day 15, 8/10 patients experienced a clinical response to the THT treatment with a majority (6/8) showing no detectable residual melanoma in representative, biopsied tumors, with two patients showing no response. About Sona Nanotech Inc.Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion – thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy, and Sona's preclinical and clinical study plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to secure the remaining required regulatory approvals for the Pilot Study, enroll study participants in a timely manner, successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.SOURCE Sona Nanotech Inc.

Original: Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy Synergies

Sona Nanotech's THT Cancer Therapy Demonstrates Strong Efficacy And Durability In Combination with Immunotherapy In Peer-reviewed Preclinical StudyApril 7, 2026 8:18 AM
PR Newswire (Canada)

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/HALIFAX, NS, April 7, 2026 /CNW/ - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is excited to announce publication of a preclinical study using its Targeted Hyperthermia Therapy ("THT") to treat cancer, in the Journal of Nanobiotechnology (https://bit.ly/47M2VoQ) which demonstrated treatment durability to the end of the 45 day study period when it was given in combination with immunotherapy. Building on its prior body of preclinical research treating melanoma and breast cancer (as published in Frontiers in Immunology), this study was conducted in an immunologically 'cold' colorectal cancer (CT26) tumor model. In this combination protocol, CT26 tumor-bearing animals were treated with two consecutive treatments of THT plus standard PD-1 inhibitor immunotherapy followed by three additional PD-1 treatments (the "Study").  Animals were followed for 45 days following initiation of treatment as per study protocol.  At completion of the Study 38% of animals given the combined therapy were alive and disease free.Sona Nanotech CEO, David Regan commented, "We've all recently heard the shocking news that colon cancer is now the leading cause of cancer death for adults under 50. This timely preclinical evidence of strong immune activation in colon cancer using our THT/immunotherapy combination protocol reaffirms our confidence in pursuing Sona's THT to spark immunity in typically immunotherapy resistant cancers. We are certainly proud of the quality of this peer-reviewed research and its acceptance in the highly respected Journal of Nanobiotechnology. This study, together with the safety and tolerability data from our recently completed, first-in-human study of THT as a monotherapy in melanoma, lays the foundation for our next trial that will combine our THT with immunotherapy."Study principal investigator, lead author and Sona Chief Medical Officer, Dr. Carman Giacomantonio, commented, "We have focused our preclinical research on immunogenically cold cancers i.e. cancers that do not respond to today's standard-of-care immunotherapy, to prove our hypothesis that Sona's THT activates immunity. This is the third preclinical cancer-type in which we have confirmed our hypothesis, and our first publication delving deeply into the biology of our treatments.  In this study, where no animals responded to a standard immunotherapy alone, 100% of animals in the THT treatment group responded to that same immunotherapy. This relates incredibly favorably to the less than ~15% success rate of immunotherapy when used to treat colorectal cancer in most humans due to low immunogenicity, giving us tremendous hope for its ability to change lives if translated successfully into a human therapy. Importantly, 38% (8 of 21) of those tumors completely cleared by day 24 following initiation of treatment and remained cancer-free to the end of the study. This is remarkably fast by any standard of measure, and these important findings will inform the protocol for our next clinical study."About Sona Nanotech Inc.Sona Nanotech, a nanotechnology life sciences company, is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion – thus enabling drugs to reach all tumor compartments more effectively. The size, shape, and surface chemistry of the nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy, Sona's preclinical and clinical study plans, future patent filings and its product development plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.





SOURCE Sona Nanotech Inc.

Original: Sona Nanotech's THT Cancer Therapy Demonstrates Strong Efficacy And Durability In Combination with Immunotherapy In Peer-reviewed Preclinical Study

SONA.CA a blast from the past....new saliva test coming to market

Two year low.

Anyone know what is going on here with this huge drop? Can't find any news. I bought some regardless.

Saliva test 99% accuracy coming to a theater near you. This monster is about to wake up. Management has been quiet but will be dropping a bombshell soon. Version 2 saliva test will be the game changer. 52 week highs will hit.

Taken from another Board. Competition for Sona in UK now for rapid saliva test Does both antigen and antibody on same test

https://www.vatic.health/knownow-testing

https://www.med-technews.com/news/Covid-19-Medtech-News/uk-healthtech-firm-to-launch-on-the-spot-covid-19-saliva-tes/

An interesting thing to consider... Since the CE Marking is a self-certified, how quickly will Sona apply for CE Marking for its Saliva version? Could it be this month? I think there is a good chance.

Sona has a connection with the UK through Darren Rowles. Let's see that connection come to fruition with some huge orders. I see SDFA APPROVAL possibly on the horizon and a resubmission for HC and FDA EUA for their nasal test with a bigger sample size followed by their Saliva test. It's going to be a big year for Sona. I don't see how this doesn't fly past $10 again.

This is HUGE news. I had to get a starter position today at $2.81. I'm curious to read the large orders early next month. Sure wish I had found this one earlier :). GLTA SNANF$$$$

Congratulations to all of those that have held! Time to hear something about sales.

CE mark. Here comes $5

May be the last time we see Penny land. This breaks $1 soon

I don't think it was intentional or miss leading by management but you never know, https://www.globenewswire.com/news-release/2020/12/04/2139812/0/en/Sona-Nanotech-Inc-Investors-Company-Investigated-by-the-Portnoy-Law-Firm.html
In the mean time look at a 3 center in the covid mix that makes Quantum Dots. QTMM

whoops

It's fugly....only going to get worse for awhile without real news or hard timelines + tax loss selling will kick in....

This is brutal. All the bagholders here like myself who got in under $1 and watched it rise to $7 without selling in the hopes of it going double digits are now being reminded what a cruel b*tch the market can be when you're greedy

Hero or zero time...been here before...lol

If sona gets HC approval it's going to be a 10 bagger from here.

We should hear news by end of day and possibly resume tomorrow morning. But it's a holiday so we will have to see what happens with the Canadian side. If it pops up the shorts here will get burned so bad considering they won't be able to cover until Friday.

any guess how long?... hours...days...weeks...lol

Halted!!

Once NML results get back HC should give Sona the rubber stamp of approval. Then sona flies past 52 week highs. If MRI global and Saudivax tests came back positive exceeding both HC and FDAs requirements, it's a no brainer NML will have the same results. Science doesn't change. Sonas test works and it will once again pass a 3rd round of rigorous testing. HC approval is imminent, just a matter of when.

Rumor is health Canada already finished their in house testing on Sonas test to reverify MRI globals results and passed with even better results. Just waiting on Justin Trudeau now to give it the stamp and find out a roll out plan and manufacturing for Sona. Going to be an interesting next few weeks. SONA CEO stated they expect to deliver their tests in November as they have partnerships with international companies for manufacturing set in place. Unicorn in the making here. Unknown to everyone now but in 30 days it will be known as the best test in the world that works on asymptomatic people and results in 15 mins

Lots of rumors going around. Approval soon. Going to be a 5 bagger from here.

HC approval tomorrow?? Status changed to Under Review again. Hopefully HC has all of their questions answered.

I agree. I am hoping for Wednesday along with an order for 10 million kits for the government.

When the Canadian market opens tomorrow this gaps up to 8.50 :)

This is the week we get health Canada approval. Buckle up!

Up she goes

Beautiful close. See you all at $20 when HC approves this.

https://sonanano.com/product-inquiry-form/

Order 1+ million sona tests available worldwide. It's coming boys and girls.

Abbott won't even have enough tests for Canada yet alone the USA. Canada has letter of intents with of course Canada, Saudi Arabia and the UK. Sona also has production facilities worldwide (partners) I expect to see a minimum of 50 million tests for Sona upon approval

Do you the no HC approval comes with an order of 20+ million tests for the government like Abbott is getting?

Prepare for Health Canada approval this week. Going to be an epic short squeeze. I bet this runs to $20+

SONA in the late stages of approval process for Health Canada. Once HC gets all of their manufacturing questions answered... approval. Hoping for Monday. Should be this week. SONA has manufacturing lined up in North America and the UK. Likely also in the Middle East and possibly in India. Could be huge once we have approvals from HC, FDA and SFDA.

October is going to be interesting.

Sales are waiting for approvals. SONA has already said once they have approvals they have large customers ready with checks to send for their tests. So they will get the money before they manufacture. Hoping Monday is the day for HC approval.

technicals, breakout ...what about approvals, sales - they have zero money - they need to raise some - who would put money in at $500m valuation? mkt has lost its sense

Technicals in play. Chart is primed for a big run. Stack that with news approval with Health Canada or FDA and this can run to $20

Agreed. https://twitter.com/IamtheFoz/status/1311727011522662402/photo/1

Looking like the last chance to get in before HC approval. FDA and SFDA soon to follow. Once orders and manufacturing announced, NASDAQ listing. Going to be a very exciting month for Sona.

Patience will prevail here. FDA, Health Canada and Saudi FDA pending approval from either of the 3. Applications sent 4 weeks ago from today.

Technicals in play... EUA approval going to gap this up to $20

Chart is primed for a breakout soon. Resistance levels should crumble over the next day or two.

Halt any day now. Then EUA FDA approval and Sona flies to $20+...all paperwork has been submitted. Then the big orders start to roll in from Saudi arabia Canada UK Australia

Also include:

1) Saudi orders 50 million+

2) Canadian orders 50 million+

3) UK or Australia orders 50+ million

All in September. Then uplist to Nasdaq.

I bet they have at least 100 million orders based on their letter of intents already.

Let's just say $25 each test x 100 million

2.5 billion in sales. I don't see why this doesn't hit $100+ share price. Float is so small here.

Order of approvals:
1. SFDA
2. FDA
3. HC

All in September